EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Outcome of COVID-19 in patients with autoimmune bullous diseases

Dipankar De, Raihan Ashraf, Hitaishi Mehta, Sanjeev Handa, Rahul Mahajan

Indian Journal of Dermatology, Venereology and Leprology · 2023

DOI: 10.25259/ijdvl_551_2022 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, 2023. Verfasst von Dipankar De und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology Venereology & Leprology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: COVID-19, Autoimmune Diseases, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on outcomes of Coronavirus disease 2019 (COVID-19) infection in autoimmune bullous diseases (AIBDs) patients is scarce. Materials and methods This single-centre survey-based-observational study included patients registered in the AIBD clinic of the Postgraduate Institute of Medical Education and Research, Chandigarh, India. All registered patients were contacted over telephone between June and October 2021. A survey was conducted after obtaining informed consent.

Results

Among 1389 registered patients, 409 completed the survey. Two hundred and twenty-two (55.3%) patients were females and 187 (45.7%) were males. The mean age was 48.52 ± 14.98 years. Active disease was reported by 34% patients. The frequency of COVID-19 infection in responders was 12.2% (50/409), with a case-fatality ratio of 18% (9/50). Rituximab infusion after the onset of pandemic significantly increased the risk of COVID-19 infection. Active AIBD and concomitant comorbidities were significantly associated with COVID-19 related death. Limitation Relative risk of COVID-19 infection and complications among AIBD patients could not be estimated due to lack of control group. The incidence of COVID-19 in AIBD could not be determined due to lack of denominator (source population) data. Other limitations include telephonic nature of the survey and lack of COVID-19 strain identification.

Conclusion

Use of rituximab is associated with higher probability of COVID-19 infection, while advanced age, active disease and presence of comorbidities may increase the risk of COVID-19 mortality in AIBD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Autoimmune DiseasesSkin Diseases, VesiculobullousMaleFemaleHumansAdultMiddle AgedRituximabSurveys and Questionnaires

Stichwörter der Autor:innen

Autoimmune bullous diseaseCOVID-19bullous diseasespemphigusrituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Dermatology Venereology & Leprology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Zitieren

APA

De, D., Ashraf, R., Mehta, H., Handa, S., & Mahajan, R. (2023). Outcome of COVID-19 in patients with autoimmune bullous diseases. Indian Journal of Dermatology, Venereology and Leprology. https://doi.org/10.25259/ijdvl_551_2022

Vancouver

De D, Ashraf R, Mehta H, Handa S, Mahajan R. Outcome of COVID-19 in patients with autoimmune bullous diseases. Indian Journal of Dermatology, Venereology and Leprology. 2023. doi:10.25259/ijdvl_551_2022

BibTeX
@article{De2023,
  author = {De, Dipankar and Ashraf, Raihan and Mehta, Hitaishi and Handa, Sanjeev and Mahajan, Rahul},
  title = {Outcome of COVID-19 in patients with autoimmune bullous diseases},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2023},
  doi = {10.25259/ijdvl_551_2022}
}
Kostenlos starten →